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and Biochemistry, San Francisco State University, San Francisco, CaliforniaABSTRACT At 150 kDa, antibodies of the IgG class are too large for their structure to be determined with current NMR meth-
odologies. Because of hinge-region ﬂexibility, it is difﬁcult to obtain atomic-level structural information from the crystal, and ques-
tions regarding antibody structure and dynamics in solution remain unaddressed. Here we describe the construction of a model of
a human IgG1 monoclonal antibody (trastuzumab) from the crystal structures of fragments. We use a combination of molecular-
dynamics (MD) simulation, continuum hydrodynamics modeling, and experimental diffusion measurements to explore antibody
behavior in aqueous solution. Hydrodynamic modeling provides a link between the atomic-level details of MD simulation and the
size- and shape-dependent data provided by hydrodynamic measurements. Eight independent 40 ns MD trajectories were
obtained with the AMBER program suite. The ensemble average of the computed transport properties over all of the MD trajec-
tories agrees remarkably well with the value of the translational diffusion coefﬁcient obtained with dynamic light scattering at 20C
and 27C, and the intrinsic viscosity measured at 20C. Therefore, our MD results likely represent a realistic sampling of the
conformational space that an antibody explores in aqueous solution.INTRODUCTIONEarly studies of antibodies were able to establish, using the
results of classical hydrodynamic methods, optical rotatory
dispersion, and fluorescence anisotropy, that antibodies of
the IgG class have a molecular mass of ~150 kDa, exhibit
a Y-shaped structure composed of three globular domains
linked together by a flexible hinge, and are mostly composed
of b-sheets (1,2). Later studies using crystallography were
able to definitively provide high-resolution details of the
domain structure of antibodies (3). However, there are only
a few cases in which a whole antibody’s structure has been
successfully resolved in atomic detail (4–6). Although they
are among the most studied of all macromolecules, there
is still a lack of information regarding the structure and
dynamics of whole antibodies in the literature.
Obtaining crystals of full-length antibodies that yield
atomic-level detail for the entire structure has proved to be
an exceedingly difficult task. Among the few success stories
in this regard (5,6) are reports of a naturally hinge-deleted
antibody (7) and a mouse IgG2a antibody (4) that appears
in its crystals to have antigenic activity toward an epitope
on its own Fc domain, a feature that is likely responsible
for the molecule’s orderly crystallization. These successes
in particular, due to the exceptional features of the antibody
in each case, confirm that the flexibility conferred by the
hinge region is the source of the difficulty of crystallizing
antibodies. On the other hand, fragments of antibodies are
fairly readily crystallized, and many instances of antibody
fragments with high-resolution detail can be found in the
Protein Data Bank (PDB) (3).Submitted January 13, 2010, and accepted for publication May 3, 2010.
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0006-3495/10/08/0905/9 $2.00NMR is the method of choice to investigate the structure
and dynamics of molecules in solution, but currently the
molecule size limit that can be studied is ~35 kDa (8). In
the study described in this work, we use a combination of
all-atom and continuum mechanics-based modeling tech-
niques along with experimental hydrodynamic methods to
establish a methodology that is capable of filling in details
of antibodies’ aqueous phase structure and dynamics that
are otherwise not accessible.
A number of studies in the literature determined whole
antibody structure using a combination of solution phase
data and modeling (9–14). Boehm et al. (9), Furtado et al.
(10), and Sun et al. (11) used x-ray and neutron scattering
along with constrained modeling to match measured scat-
tering data and produce very detailed families of models of
IgA, IgD, and IgG structure. Additionally, a body of work
by Longman et al. (12) and Lu et al. (13,14) employing
coarse-grained hydrodynamic bead modeling of rigid ellip-
soidal subunits, with sizes and axial ratios determined with
data from the crystal structures of actual antibody domains,
has identified single conformations for IgG structures that
possess properties consistent with those measured experi-
mentally. Although some success can be achieved in distin-
guishing antibodies that differ significantly in the length of
their hinge (13,14), these models do not take the intrinsic
flexibility of the antibody into account and thus provide little
insight into its fluctuating structure in solution. In contrast,
our approach uses an all-atom model of the antibody whose
structure is modeled by explicit solvent molecular-dynamics
(MD) simulation. Once we have validated such a construc-
tion against experimental data, we will be able to extract
significant structural and dynamical information from the
MD trajectories. With similar goals in mind, Chennamsettydoi: 10.1016/j.bpj.2010.05.003
906 Brandt et al.et al. (15,16) recently investigated antibody solution phase
properties using protocols for model building and simulation
similar to those employed in our study.
The work described here includes the construction of an
all-atom model of a recombinant humanized anti-HER2
IgG1 monoclonal antibody, trastuzumab (Genetech, South
San Francisco, CA) (17,18). Using MD simulation, the struc-
ture, as initially pieced together from the crystal structures of
fragments, was equilibrated in silico in an aqueous solution
and allowed to relax into a conformation that is more likely
characteristic of the antibody it represents when in actual
aqueous solution.MultipleMD trajectories were started using
the result of the initial trajectory as their starting structure.
Each of the trajectories produced represents a distinct
exploration of the phase space accessible from the common
starting structure. To evaluate whether the structures gener-
ated in the series of MD simulations are possibly representa-
tive of actual conformations of human IgG1 samples in
solution, we compute the transport properties of the structures
using a precise boundary element hydrodynamic modeling
technique. Since the hydrodynamic modeling technique
used computes the properties of a particle based on the dimen-
sions and topology of its solvent-accessible surface, it is an
ideal technique to analyze the results of MD simulations of
large, flexible molecules such as antibodies, whose transport
properties are expected to fluctuate as they sample their avail-
able conformational space. Such an analysis is very useful
because the results are directly comparable to those obtained
with experimental hydrodynamic methods.
In this work, we show that accurate hydrodynamic compu-
tations can be used to validate atomistic structural data
against experimental hydrodynamic data and thus evaluate
the quality of the specific AMBER force fields used in
this study. Therefore, in addition to presenting the initial
results from our studies of the solution phase structure and
dynamics of a human IgG1 monoclonal antibody, we also
describe a methodology for the in silico construction of an
antibody for which there is no complete crystal structure.
One of the major findings of this work is that the presently
available force fields are accurate enough to arrive at realistic
solution structures even after separate domain pieces are put
together with multiple mutations to reach a specific amino
acid sequence of interest. This technique should be broadly
applicable to various classes of antibodies whose crystal
structures are lacking.MATERIALS AND METHODS
Trastuzumab model construction
Superposition of the crystal structures of domain fragments onto a template
structure, referred to in this work as the KOL/Padlan structure (3,19), was
accomplished using Swiss PDB viewer (20). The same software was also
used to make mutations and add missing amino acids in the Fc domain so
that its composition would be identical to that of the target antibody, trastu-
zumab. With the trastuzumab domains oriented relative to each other so thatBiophysical Journal 99(3) 905–913the coordinates of the template’s hinge could be used to join the domains
together, the PDB files for each domain and the hinge residues needed to
complete the trastuzumab model were saved individually. Each PDB file’s
list of coordinate data was combined into a single file using a text editor.
The protein and oligosaccharide residues were listed in the order of each
chain’s primary sequence so that the necessary peptide bonds would be
made by AMBER’s tleap (21) during topology/parameter building.
AMBER’s ff99 (22) and Glycam04 (23) force fields were used for the initial
energy minimization and MD simulation trajectory.MD simulations
For the initial T0 simulation, SANDER from the AMBER7 suite was used
for the minimization, equilibration, and production dynamics. Energy mini-
mization of the initial structure using generalized Born (GB) solvation was
carried out to remove high-energy bonds and clashes that were artifacts of
the model’s construction process. The minimization procedure used 100 iter-
ations of steepest descent followed by 100 iterations of conjugate gradient
with an electrostatic cutoff of 12 A˚ and a solvent dielectric constant of 78.
The system was solvated in an orthorhombic box of TIP3P water molecules
with a 12 A˚ buffer of solvent between the solute’s furthest dimensions in
each direction. The result was a 167.4  182.5  92.5 A˚ box that contained
74,577 water molecules and 12 chloride anions to make the system neutral.
An initial MD equilibration of the solvent was carried out with all protein
and carbohydrate atoms restrained in a 50 kcal/mol energy well as the
system was heated from 100 to 300 K over a period of 1.5 ps, with pressure
held at 1 atm and taking 1 fs time steps for integration of atomic equations of
motion. Next, six rounds of energy minimization on the entire system, each
using 100 iterations of steepest descent followed by 100 iterations of conju-
gate gradient, were carried out with the restraints on the solute reduced in
increments of 5 kcal/mol in each round from 25 kcal/mol in the first to
0 kcal/mol in the last. A final 20 ps MD equilibration followed in which
the temperature of the system was increased from 100 K to 300 K. The
density of the system increased from 0.8770 g/cm3 to 0.9999 g/cm3 during
equilibration of the solvated system.
Production MD simulations with pressure and temperature held constant
at 1 atm and 300 K were carried out from this point on. For this stage of
simulation, the SHAKE algorithm was used and the size of the time steps
for integrating the atomic equations of motion was increased to 2 fs. For
each stage of equilibration and production dynamics once the system was
solvated, the cutoff distance for calculating electrostatic interactions directly
was set to 9 A˚. Particle mesh Ewald summation was used to calculate elec-
trostatic interactions beyond this distance. The cutoff for calculating van der
Waals interactions was also set to 9 A˚. An MD trajectory of 7.4 ns was
computed with coordinates written to a file at 0.5 ps time intervals.
The potential energy of structures stripped of solvent and counterions was
determined with AMBER’s MM-PBSA script. The molecular mechanical
energy of a structure, including the internal potential, nonbonded potential,
and energy of solvation using the GB method, were determined with
SANDER. An internal dielectric of one and a solvent dielectric of 80
were used for these calculations. No cutoff distances for nonbonded interac-
tions were used.
MultipleMDsimulations (T1–T8)were also carried out,with the following
differences: The protein portion of the final structure of the initial trajectory
was reparameterized with the improved parameter values of the ff99SB
(24) force field, and parameters for the carbohydrates were again taken
from the Glycam04 force field. The system was solvated in a truncated octa-
hedral box of TIP3P water molecules with a 10 A˚ buffer of solvent between
the solute’s farthest dimensions in each direction. The result was a truncated
octahedral box of water that contained 99,132 water molecules. The system
was neutralized with 12 chloride ions. The final system contained 99,120
water molecules (297,360 atoms), 12 chloride ions, and 1348 residues of
protein and sugar (20,692 atoms), which altogether amounts to a system
with 318,064 atoms. The initial equilibration with solvent and preparation
for production MD were achieved as described above for the T0 simulation.
Trastuzumab MD and Hydrodynamics 907At this point, eight parallel MD trajectories were started from the result of
the previous steps using AMBER10’s PMEMD.With the SHAKE algorithm
applied and taking time steps of 2 fs, a 100 ps MD equilibration in which the
temperature of the system was increased from 100 K to 315 K was carried
out using different seed numbers for the randomization of atomic velocities
in each of the eight trajectories. In the next 100 ps of MD equilibration, the
temperature was cooled from 315 K to 300 K. Production MD simulations
with pressure and temperature held constant at 1 atm and 300 K were carried
out from this point on. Velocities of all atoms were again randomized at the
start of the production dynamics and coordinates were written every 2 ps
while each of the eight trajectories was run for 40 ns of simulation time.
The van der Waals and electrostatic cutoffs were the same as for the T0
simulation.4.8
5.0
)Boundary element calculations
The methodology used for these calculations is discussed in detail in
previous works (25–27). The modeling procedure used assumes that a
1.1 A˚ layer of water is uniformly distributed over the surface of the protein.
The solvent-accessible surface of each structure was defined by MSROLL
(28) using a 1.5 A˚ diameter ball rolled over the surface of the solute. This
surface was triangulated by MSROLL using a fineness parameter value of
3.0. For the analysis of single structures only, the output of MSROLL, which
contained ~40 k triangles for each of the full-length antibody structures
studied in this work, was input to COALESCE (25) to produce five triangu-
lations with ~9 k, 11.8 k, 12.5 k, 14.3 k, and 16 k triangles. The hydrody-
namic boundary element program BEST (25–27) was used to compute the
translational diffusion tensor, rotational diffusion tensor, and intrinsic
viscosity of the molecules analyzed. The computed hydrodynamic proper-
ties, as a function of the inverse of the number of triangles, were plotted
and fit to a straight line to extract the intercept, which is a precise value
for the property corresponding to the smooth hydrodynamic surface.
When 9 k or more triangles are used, the properties fall on a neat straight
line, providing high-precision extrapolation to an infinite number of
triangles.
For the analysis of an MD trajectory, coordinate files in PDB format were
generated using the AMBER suite’s ptraj program. PDB files with the tras-
tuzumab model only were generated from each trajectory at 50 ps intervals.
To avoid overrepresentation of the starting conformation, analysis of the first
10 ns of each trajectory was not included in the results reported. The solvent-
accessible surface of each structure in the extracted PDB files was deter-
mined and tiled with triangles using MSROLL as described above. The
resulting triangulations were processed by COALESCE to produce a
single triangulation for each structure with ~9 k triangles. The transport
properties for each structure were computed with BEST. Because of the
large number of structures analyzed, the results were approximately extrap-
olated to an infinite number of triangles as described below and in Aragon
and Hahn (26).3.6
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FIGURE 1 DLS extrapolations for the determination of trastuzumab’s
translational diffusion coefficient at 20C (squares) and 27C (circles);
each measurement is in triplicate.Determination of trastuzumab’s translational
diffusion coefﬁcient by dynamic light scattering
For dynamic light scattering (DLS), a solution of trastuzumab was exten-
sively dialyzed against a pH 7 solution of 20 mM NaPi and 100 mM
NaCl, maintained at 5C. Five dilutions with concentrations in the range
of 1–10 mg/mL were prepared and their concentrations were determined
with an ultraviolet-visible spectrometer. For each sample, autocorrelation
functions of fluctuations in the intensity of the 514.5 nm line of a Lexel
95 argon ion laser (Cambridge Lasers Laboratories Inc., Fremont, CA) scat-
tered at a 90 angle from the solutions were determined by a Brookhaven
Instruments (Holtsville, NY) BI-9000 AT digital autocorrelator and software
that determined the mutual diffusion coefficient from the autocorrelation of
the scattered intensity. The temperature of the samples was held constant to
a tolerance of 50.1C with a Brinkmann (Metrohm USA, Riverview, FL)
RM6 thermostated water bath.The translational self-diffusion coefficient (Dt) for trastuzumab was
obtained by extrapolating the values obtained for the mutual diffusion
coefficient to zero concentration, as shown in Fig. 1. The self-diffusion
coefficient obtained was adjusted using viscosity values for the buffer
(1.013 mPa s) and water (1.002 mPa s) at 20C so that the diffusion coeffi-
cient reported would correspond to trastuzumab in water at 20C.
Measurements were carried out at 20C and 27C. The results obtained
were found to agree to within 0.4% when scaled according to the Stokes-
Einstein relation:
Dt;20C
Dt;27C
¼ 300K  hH2O;27C
293K  hH2O;20C
Results were obtained at two temperatures to confirm that the range of
conformational space sampled at each temperature is not significantly
different, and therefore it is acceptable to determine the transport property
values for the antibody at 20C by hydrodynamic modeling using structures
generated with MD simulations run with a temperature of 300 K.Determination of trastuzumab’s intrinsic viscosity
by dilute solution viscometry
A solution of trastuzumab was extensively dialyzed against a pH 7.4 solu-
tion of 20 mM KPi and 100 mM KCl while it was kept at 5
C. Five dilutions
with concentrations (c) in the range of 1–3 mg/mL were prepared. The
viscosity of the buffer (h0) and the viscosity of each dilution (h) was
measured with an Anton Paar (Ashland, VA) SP3-V sample changer and
AMVn rolling ball viscometer with temperature set to 20C. The intrinsic
viscosity [h] of trastuzumab was determined as:
½h ¼ lim
c/0
h h0
h0c
RESULTS AND DISCUSSION
Model building
A complete crystal structure of trastuzumab, a humanized
IgG1 antibody, does not exist. Therefore, to generate starting
coordinates for this study, we obtained a crystal structure forBiophysical Journal 99(3) 905–913
908 Brandt et al.the Fab domain of trastuzumab, as well as the crystal struc-
ture for the G2-glycosylated Fc of a closely related antibody.
To make this Fc fragment identical to that of the Fc of tras-
tuzumab, mutations were made and missing residues added.
The structures available for use as references to obtain the
starting coordinates for the 34 missing hinge residues (17
from each heavy chain (HC)) are limited in number. The
PDB entries that contain potentially useful information
include three full-length structures: human IgG1 b12 (6)
(PDB entry 1HZH.pdb), mouse IgG1 61.1.3 (5) (PDB entry
1IGY.pdb), andmouse IgG2a 231 (4) (PDB entry 1IGT.pdb).
Another PDB entry with information of interest is human
IgG1 KOL (29) (PDB entry 1IG2.pdb), which forms crystals
fromwhich only the F(ab0)2 fragment (which includes both of
the Fab domains and the upper and middle hinge residues)
yields an interpretable electron density. The lower hinge
and Fc domain of KOL do not appear in the Fourier map of
electron density, most likely because the region adopts
more than one conformation in its crystals.
The upper-hinge region of human IgG1 molecules
contains a sequence (KTHT) that immediately precedes the
middle-hinge region (3). In the KOL and b12 structures,
this sequence forms a single-turn, open helix. However,
b12 has the KTHT helix in only one of its upper-hinge HC
strands and it is partially unwound, whereas the other strand
does not yield an interpretable diffraction pattern for the
THT region of the sequence. The KOL structure has a C2
symmetry axis that goes through the hinge and therefore
has the KTHT helix in both of its HCs. We chose the KOL
structure as the source of coordinates for the atoms of the
upper- and middle-hinge regions, and as a template for
orienting the Fab domains relative to each other. The coordi-
nates for the atoms of the lower hinge of our starting struc-
ture were obtained from a hypothetical build of the region,
assembled in silico by Padlan (3,19), to link the KOL
F(ab0)2 (29) with a crystal structure of a human IgG1 Fc.
This structure’s hinge has the exact amino acid composition
required to complete our model of trastuzumab. The f/j
dihedral angles of the lower hinge in space, as constructed
by Padlan, are characteristic of b-sheets, which is consistent
with the secondary structure composition of the majority of
an IgG’s structure (1,3). As shown below, the structure of
the hinge region is well determined by the accurate force
field used in this study, AMBER’s ff99SB (22).
Electron microscopy studies (30) have indicated that IgGs
populate many conformations, and fluorescence anisotropy
studies (2) have indicated that IgGs possess segmental flex-
ibility with internal motions that occur on a timescale of tens
of nanoseconds. Therefore, if there do exist preferred confor-
mations (e.g., such as that displayed by b12) with interdo-
main orientations or contacts that are preferred rather than
a continuous range of equally probable conformations, it
should be possible to observe relaxation into one or more
of them within the timescale accessible in an MD simulation.
Therefore, we decided it would be of interest to start ourBiophysical Journal 99(3) 905–913simulation from a slightly unnatural conformation, which
likely would be ensured by using the theoretical lower hinge
of the KOL/Padlan structure, so that it would be possible to
observe relaxation into more favorable conformations.MD simulations
Throughout the duration of the initial trajectory, the Fab
and Fc domain structures appear to be very stable, as can
be seen in a plot of their root mean-square deviation
(RMSD; Fig. 2 C) using their initial coordinates as a refer-
ence. Although high-frequency vibrations are apparent
throughout the structure, they are of relatively low ampli-
tude. In comparison, the lower-hinge region appears to be
quite flexible. The motions of this region appear to be larger
in amplitude, which is not unexpected since there is no
secondary structure in this region and it is highly exposed
to solvent. On the other hand, the Fab domains initially reor-
ient slightly relative to each other, but otherwise appear to
move as a single unit. About 1.5 ns into the trajectory, the
Fc domain rotates ~45 about its long axis and begins to drift
toward one of the Fabs. At ~5 ns into the trajectory, another
conformational change begins that results in the upper hinge
bending so that the molecule adopts a slightly trigonal pyra-
midal shape rather than the trigonal planar shape of the
starting conformation. Correlations to the two largest-scale
motions noted above are apparent in a plot of the entire struc-
ture’s RMSD (Fig. 2 C). A large shift is observed in the first
2–3 ns, which is likely due to the movement of the Fc and
lower hinge. The structure then stays roughly in that confor-
mation until ~5 ns into the trajectory, which is consistent
with the plateau in the value of the RMSD during this period.
At ~5.5 ns, a shift in the RMSD occurs that corresponds well
with the conformational shift that results in the upper hinge
bending.
The plateau in the value of the entire structure’s RMSD is
a possible indication that the high potential energy artifacts
due to interdomain contacts or orientations present in the
initial coordinates have been relaxed (31). A molecular
mechanics (MM) analysis of structures from along the trajec-
tory confirms that the model has descended into an energy
basin on its potential energy surface (Fig. 2 D). To test
whether the drop in potential energy could be due to relaxa-
tion of the domains rather than relaxation of interdomain
orientation and interactions, we ran a simulation of the tras-
tuzumab Fab alone, using the same parameters and condi-
tions as for the initial trastuzumab simulation, and analyzed
it using the same method employed for the whole trastuzu-
mab simulation. There was no comparable relaxation in
potential energy for the Fab-only simulation (Fig. 2 E).
Ahydrodynamic analysis of the starting (TrastuzumabT0,t¼0)
and final (TrastuzumabT0,t¼7.4) structures indicates that the
final structure has properties in closer agreement with exper-
imentally determined, ensemble-averaged hydrodynamic
measurements (Table 1). Therefore, the structure that results
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FIGURE 2 (A) Trastuzumab (T0,t¼0). (B) Tras-
tuzumab at t¼7.4 ns of simulation T0. (C)
RMSD, during initial trajectory, of the trastuzumab
model as a whole (circles), Fab1 (diamond), Fab2
(square), and Fc (triangle). (D) MM-GBSA anal-
ysis of the trastuzumab model during initial trajec-
tory. (E) MM-GBSA analysis of the trastuzumab
Fab-only simulation; molecular graphics produced
with UCSF Chimera (33).
TABLE 1 Hydrodynamic modeling results for single
structures, and summary of our experimental hydrodynamic
results and results from the literature
Antibody Dt (107 cm2/s)* tr (ns)y [h] (cm3/g)
b12 (1hzh.pdb) (6) 4.021 (50.009) 183.4 (50.4) 6.425 (50.005)
61.1.3 (1igt.pdb) (4) 3.966 (50.003) 191.5 (50.0) 6.681 (50.004)
213 (1igy.pdb) (5) 4.221 (50.002) 157.6 (50.0) 5.662 (50.002)
KOL/Padlan (17) 3.873 (50.002) 213.9 (50.5) 7.275 (50.004)
Trastuzumab
(T0,t¼0)
3.989 (50.008) 192.0 (50.2) 6.739 (50.003)
Trastuzumab
(T0,t¼7.4)
4.006 (50.002) 187.3 (50.4) 6.277 (50.005)
Trastuzumab
experiment
4.09 (50.01) 6.37 (50.2)
IgG literaturez 168 (2), 180 (38) 6.20 (50.5) (39)
All values correspond to a temperature of 20C in pure water.
*For computational results: Dt ¼ 1/3 Tr(Dtt).
yFor computational results: tr ¼ (6Dr)1, where Dr ¼ 1/3 Tr(Drr).
zExperimental results for rabbit IgG (2), bovine IgG (38), and human
IgG1 (39).
Trastuzumab MD and Hydrodynamics 909from the initial trajectory is most likely more characteristic
of an antibody in solution than is the conformation of the
initially pieced-together structure.
To maximize the amount of conformational space sampled
(32), eight further simulation trajectories were generated in
parallel, with the relaxed trastuzumab model used as the
initial conformation for each. The motions observed in the
7.4 ns trajectory indicated that a larger simulation cell is
required to ensure that the model does not interact with an
image of itself. Visual inspection of these eight 40-ns trajec-
tories (Movie S1 in the Supporting Material) clearly reveals
distinct explorations of simulation phase space. Though
the same starting structure was used for each trajectory,
the use of different seed numbers for the randomization of
atomic velocities during temperature and pressure equilibra-
tion of each system and at the outset of production dynamics
was sufficient to send each antibody structure onto unique
pathways in conformational space.
In the hierarchy of motions in the trajectories, the rotation
of the Fc relative to the Fab domains appears to be the fastest
of the large domain motions. A slightly slower domain
motion is present in the translational diffusion of the Fc rela-
tive to the Fab domains. The Fab-Fc angle is observed at
angles ranging from nearly 0 to 180. Of the domain-domain
reorientation motions observed, that between the Fab
domains changes on the slowest timescale during the lengthof our simulations. In fact, on short timescales, the Fab
domains appear to behave as a single F(ab)2 unit. When
observed over a longer timescale and multiple trajectories,
however, it is clear that the two domains’ orientation to
one another does change, primarily by rotation about non-
shared axes that are ~140 apart and cross roughly at the
point where the two Fab domains are closest.Biophysical Journal 99(3) 905–913
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910 Brandt et al.The Fab-Fab orientation in our model seems to be strongly
influenced by these domains’ contact with each other above
the hinge region. During the course of the eight 40-ns simu-
lation trajectories, the two domains are rarely out of contact
with each other. The region in which the Fab domains make
contact with each other is rich in aspartate, glutamate, and
lysine residues. Therefore, it is likely that the interaction
observed between the Fab domains is stabilized by electro-
static forces. This interaction could be prevalent in the
multiple trajectories simply because it is common to all of
the conformational space that is locally accessible from the
starting structure. We address the question of whether the
conformations observed in the simulations could be repre-
sentative of a human IgG1 in solution at length in the
following sections.
Time (ns)
FIGURE 3 Plots of the eigenvalues of the rotational diffusion tensor, Dr,
of structures from simulation T5; Fig. S1 has corresponding plots for all
simulation trajectories T1–T8.
TABLE 2 Summary of hydrodynamic analysis of MD
simulation data, our experimental hydrodynamic results,
and results from the literature
Trajectory Dt (107 cm2/s)*y tr (ns)zy [h] (cm3/g)y
1 4.00 (50.04) 184 (5 9) 6.6 (50.2)
2 4.12 (50.05) 168 (5 8) 6.0 (50.3)
3 4.15 (50.06) 158 (5 10) 6.1 (50.3)
4 3.97 (50.03) 190 (5 5) 6.7 (50.1)
5 4.05 (50.03) 179 (5 5) 6.4 (50.2)
6 4.11 (50.03) 168 (5 5) 6.0 (50.1)
7 4.17 (50.07) 164 (5 10) 5.9 (50.4)
8 4.09 (50.04) 172 (5 8) 6.2 (50.2)
Averagex 4.08 (5 0.07) 173 (5 11) 6.24 (5 0.3)
Experiment{ 4.09 (5 0.01) 6.37 (5 0.2)
Literaturek 168 (2), 180 (38) 6.20 (50.5) (39)
All values correspond to a temperature of 20C in pure water.
*For computational results: Dt ¼ 1/3 Tr(Dtt).
yFor individual trajectories; the value quoted is the trajectory average and its
standard deviation.
zFor computational results: tr ¼ (6Dr)1, where Dr ¼ 1/3 Tr(Drr).
xValues quoted are the average of each trajectory’s average and their stan-
dard deviation.
{See Methods and Materials; uncertainties quoted are the standard error of
extrapolations to c ¼ 0.
kExperimental values for rabbit IgG (2), bovine IgG (38), and human
IgG1 (39).Computation of hydrodynamic transport
properties
We applied hydrodynamic modeling in this study to evaluate
our MD results. We first analyzed a set of single structures to
see how close they were to experimental values, and then
computed the transport properties as ensemble averages
over full MD trajectories.
Computational hydrodynamic analyses of single struc-
tures, in which a single structure is triangulated multiple
times with a range of triangle numbers and the results are
extrapolated to an infinite number of triangles, were carried
out on each of the full-length antibody structures in the
PDB (61.1.3, 231, and b12) as well as the KOL/Padlan
structure and the trastuzumab model structure from the T0
trajectory in its initial (TrastuzumabT0,t¼0; Fig. 2 A) and final
(TrastuzumabT0,t¼7.4; Fig. 2 B) conformations. We compared
the experimental diffusion coefficients with the average
of the three eigenvalues of the corresponding tensors. To
obtain the rotational correlation time, we used the approxi-
mate formula tr ¼ ð6DrÞ1. Fig. 3 and Fig. S1 show that
the three eigenvalues of the rotational diffusion tensor
typically differ only ~25–20% from their average; thus,
any kind of specific weighting by a particular measurement
technique will yield a value very close to the above rotational
correlation time. The close agreement with experiment
(Table 2) corroborates this assertion.
The results computed for the initial and final snapshots
from our simulation T0 and whole antibody crystal structures
in the PDB are summarized in Table 1. The structure that
yields the least agreement to experimental data is the KOL/
Padlan structure, which was chosen as a source of hinge
coordinates and as a template for the initial interdomain
orientations of the trastuzumab model. The transport proper-
ties of our model’s initial structure (TrastuzumabT0,t¼0)
are in slightly better agreement with experimental values,
possibly due to the different elbow angle of the Fab domains
or the slightly closer proximity of the Fab domains to each
other relative to the Fab domains in the KOL/Padlan struc-Biophysical Journal 99(3) 905–913ture. However, the final structure of the initial trajectory
(TrastuzumabT0,t¼7.4), which is also the starting structure
for the multiple trajectories (T1–T8), matches experimental
values quite well. The best match comes from the human
IgG1 b12 structure (6). It is notable that both our
TrastuzumabT0,t¼7.4 model and b12 both match very well
with experimental values and yet have very different interdo-
main orientations. Given the flexibility we expect in an
antibody structure (2,34), the single molecule results were
included only to provide a frame of reference and to
FIGURE 4 Plots of hydrodynamic analysis results; values are adjusted for
each transport property using the average slope obtained from full hydrody-
namic analysis of the trajectories’ last structure. Note: The density of the data
points displayed is 20% of each trajectory’s data included in the numerical
data presented in Table 2.
Trastuzumab MD and Hydrodynamics 911demonstrate that the initial trajectory’s final conformation is
more likely characteristic of an antibody in solution than is
its initial state.
Many proteins and protein complexes can reasonably be
treated as rigid bodies in computations of their hydrody-
namic properties (26,27). By performing boundary-element
calculations on structures taken at regular intervals from
along an MD trajectory and averaging them, one can obtain
values for a flexible molecule. The ensemble average over
rigid bodies approach to modeling flexible bodies has a
long history. In a study of flexible dumbbells, Zimm (35)
demonstrated that the error in the approximation is very
small. Hagerman and Zimm (36) used this approach to
provide the first expressions for the rotational diffusion coef-
ficients of semiflexible polymers. Fixman (37) and others
demonstrated that the method is exact for the pre-averaged
hydrodynamic interaction, and thus the difference between
the fluctuating hydrodynamic interaction and the rigid
body ensemble approach is very small when full hydrody-
namic interactions are included. Furthermore, as long as
the force field used is sufficiently accurate, appropriate simu-
lation parameters are applied, and the simulations sample
sufficient conformational space, the collection of structures
that an MD simulation produces will be representative of
a Boltzmann-weighted ensemble. In the work presented
here, >6000 structures were used to compute the ensemble
average transport properties.
Computing the hydrodynamic properties of the thousands
of structures extracted from MD trajectories and extrapo-
lating each to an infinite triangle number (25) is very time-
consuming. Therefore, we used the average slope from
a full extrapolation to an infinite number of triangles of
each trajectory’s last structure to extrapolate each transport
property to the smooth surface. This is quite a good approx-
imation since the extrapolation correction amounts to within
only 0.5%, 1.0%, and 1.6% of the value of Dt, Dr, and [h],
respectively. The scaled results of the hydrodynamic trajec-
tory analyses are plotted for each trajectory in Fig. 4 and
Fig. S1, and their averages are summarized in Table 2.
The average Dt value at 293 K over all of the trajectories
is 4.081075 0.07107 cm2/s, which is within 0.3% of
the value determined with DLS (4.09107 5 0.03
107 cm2/s). The average Dr value at 293 K over all of the
trajectories is 9.581055 0.6105 s1, which corresponds
to a rotational correlation time (tr), according to the relation-
ship tr¼ (6Dr)1, of 1745 11 ns. This value is within 3.6%
of the value given in the literature for the rotational correla-
tion time of a rabbit IgG (168 ns) as determined by fluores-
cence anisotropy (2) at 20C, and within 3.3% of the value
reported for the rotational correlation time of a bovine IgG
(180 ns) as determined by electric birefringence (38) at
20C. The value computed from the trajectories for the
average intrinsic viscosity is 6.24 5 0.30 cm3/g, which is
within 0.7% of the value given for a human IgG1 at 20C
(6.20 5 0.50 cm3/g (39)), and within 3.0% of the valuewe determined for trastuzumab at 20C (6.375 0.19 cm3/g).
These values are summarized in Table 2. The computed
values are stated for pure water at the temperature cited,
whereas the experimental data have been corrected to pure
water using the viscosity of the buffer solution.
The excellent agreement between the computational
hydrodynamic analysis of the collection of MD trajectories
and our determinations for the translational diffusion coeffi-
cient and intrinsic viscosity of trastuzumab samples, as well
as with literature values for the translational diffusion coeffi-
cient, rotational correlation time, and intrinsic viscosity of
IgG molecules, strongly supports our contention that the
range of conformations observed in the MD simulations
represents the solution conformations undertaken by trastu-
zumab molecules in the range of 293–300 K. The data
show that the rigid ensemble approach to the computation
of properties of flexible antibodies works very well.CONCLUSIONS
In this work, we describe the successful generation of MD
trajectories for a model of a human IgG1 antibody that was
assembled from domain fragments, only one of which had
the exact amino acid composition of the target molecule.
Our model-building choices were guided by the assumption
that the crystal structures of whole antibodies that areBiophysical Journal 99(3) 905–913
912 Brandt et al.available in the PDB most likely have some exceptional
feature that makes them crystallizable, and therefore are
not necessarily the best templates to use in building our
model structure. Therefore, we chose to use the KOL/Padlan
structure, which features a hinge built in silico, as our
template. MM analysis of our initial trajectory (T0) revealed
that the model relaxed during a 7.4 ns simulation (Fig. 2 D).
When these results are compared with those obtained in
a Fab domain-only simulation (Fig. 2 E), it is clear that the
domains themselves are not the source of the relaxation.
Therefore, we conclude that shifts in the interdomain orien-
tation within the model are the source of the lower potential
energy of the resulting structure. In the multiple trajectories
that were started with the result of the initial trajectory as
their starting conformation, we observe a wide range of
conformations.
To assess whether the structures generated could be repre-
sentative of trastuzumab in solution, we analyzed structures
taken at regular intervals from each simulation trajectory
with BEST (25–27), a very precise and accurate boundary-
element, hydrodynamic modeling technique, and compared
the results with values obtained from our measurements of
samples of trastuzumab and values found in the literature
for IgG molecules. We find that the trajectory transport prop-
erty averages agree extremely well with values obtained
experimentally. Therefore, given the precision and accuracy
of the hydrodynamic method used to evaluate the simulation
results, we are able to conclude that the collection of struc-
tures generated in the multiple MD trajectories is a good
representation of the conformations achieved by antibodies
in aqueous solution. It should be noted, however, that the
kinetics of the motions observed are not expected to be accu-
rate, due to the limited accuracy of the water model used
(40). Since the TIP3P water model underestimates the
viscosity of water, the motions are all faster than would be
expected in true water. However, the advantage of hydrody-
namic modeling is that we only need accurate conformations,
not the precise timing of the motions. Thus, trajectories that
are much shorter than needed to extract the full dynamic
correlation functions can be successfully used to compute
measurable hydrodynamic properties. Our data show that
the force field used and the simulation parameters employed
sufficiently represent the structure and dynamics of trastuzu-
mab, and therefore its hydrodynamic properties are accu-
rately reproduced.
In this work, extremely good agreement between measure-
ment and computation was achieved because the physical
samples of trastuzumab were fabricated for pharmaceutical
purity; the measurements were carried out to very high
precision with DLS; the simulation used explicit water, a
realistic force field, and all-atom detail for the protein and
sugars on the Fc region; and the hydrodynamic computations
were high-precision, boundary-element computations that
used a large number of surface elements for the definition
of molecular shape.Biophysical Journal 99(3) 905–913As mentioned above, one previously reported study also
used an all-atom MD simulation to explore the solution
phase properties of whole antibody structure (15,16).
However, to our knowledge, the MD simulations reported
here are the first simulations of a whole antibody to be vali-
dated against experimental measurements that are sensitive
to the overall conformational features of molecules in solu-
tion. The agreement of our simulation results with experi-
mental determinations of the hydrodynamic properties of
the molecule modeled suggests that the methodology used
to construct our model and the simulation parameters applied
are reasonably good choices and should have broad applica-
bility across antibody classes. Likewise, these results suggest
that the combination of modeling and experiments used may
also be useful for investigating the solution phase properties
of similar antibodies or other flexible molecules.SUPPORTING MATERIAL
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